GLS1 presents a druggable therapeutic target via GLS1 inhibitors, in particular CB-839 contributed to the depletion of GSCs and glioblastoma cell growth according to the lack of nutritional supplements resulting from the reduction of glutamine penetration into the TCA cycle. This evidence concerns the gene GLS and glioblastoma.